MedTrace Logo

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

NCT02709889 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2020-10-19

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to assess the safety and tolerability of rovalpituzumab tesirine in subjects with specific delta-like protein 3-expressing advanced solid tumors.

Conditions

  • Malignant Melanoma
  • Medullary Thyroid Cancer
  • Glioblastoma
  • Large-Cell Neuroendocrine Carcinoma
  • Neuroendocrine Prostate Cancer
  • High Grade Gastroenteropancreatic Neuroendocrine Carcinoma
  • Other Neuroendocrine Carcinoma
  • Other Solid Tumors

Interventions

DRUG

Rovalpituzumab tesirine

DRUG

Dexamethasone

Dexamethasone will be provided through a participant's local prescription by Investigator or other provider (i.e., dexamethasone will not be provided by the Sponsor).

Sponsors & Collaborators

Principal Investigators

  • AbbVie Inc. · AbbVie

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-23
Primary Completion
2019-08-27
Completion
2019-08-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02709889 on ClinicalTrials.gov